...
Otsuka Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for the Treatment of Attention-deficit Hyperactivity Disorder (ADHD) in Adult Patients
An estimated 5 percent (11 million) adults in the U.S. are diagnosed with ADHD.
...
USA population = 329,000,000+ (06-17-2020) - https://www.census.gov/popclock/ (Google)
...
Approximately two-thirds or more of children with ADHD continue to have symptoms and challenges in adulthood.
https://www.businesswire.com/news/home/20200611005789/en/Otsuka-Announces-Positive-Top-line-Results-Phase-3 (06-11-2020)
...
11,000,000/329,000,000 = ~ 3 percent
5% of 329,000,000 = ~ 16,000,000
16,000,000 vs 329,000,000
11,000,000 vs 329,000,000
...
Centanafadine (INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with a ratio of 1:6:14, respectively.[1][2][3][4] In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance.[5][6] In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine.[7] As of January 2018, Otsuka's pipeline indicates it is in Phase III clinical trials.[8]
(Wikipedia)
...
https://www.ninds.nih.gov/Disorders/All-Disorders/Attention-Deficit-Hyperactivity-Disorder-Information-Page
No comments:
Post a Comment